Determining factors in the prescription of moxifloxacin in exacerbations of chronic bronchitis in the primary-care setting

Clinical Drug Investigation

Volumn 27, Issue 2, 2007, Pages 95-104

  Miravitlles, Marc ^a   Llor, Carles ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b Catalan Society of Family Medicine   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; MOXIFLOXACIN;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; CHRONIC BRONCHITIS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SMOKING; SYMPTOMATOLOGY;

ADRENAL CORTEX HORMONES; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BRONCHITIS, CHRONIC; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; QUINOLINES; SEVERITY OF ILLNESS INDEX;

EID: 33846458688     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727020-00002     Document Type: Article

References (28)

1. Sobradillo V, Miravitlles M, Gabriel R, et al. Geographical variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-9
2. Cerveri I, Accordini S, Verlato G, et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001; 18: 85-92
3. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-9
4. Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med 2002; 9: 191-7
5. Miravitlles M, Mayordomo C, Artes T, et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo Aereo. Respir Med 1999; 93: 173-9
6. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22
7. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-95
8. Doll H, Miravitlles M. Heath-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005; 23: 345-63
9. Miravitlles M. Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibacterial treatment. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5: 423-35
10. Anthonisen NR, Manfreda J, Warren CP, et al. Antibacterial therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
11. Adams SG, Melo J, Luther M, et al. Antibacterials are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-52
12. Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J 2001; 17: 928-33
13. Glantz SA, Slinker BK. Primer of applied regression and analysis of variance. New York (NY): McGraw-Hill International Book Co, 1990: 512-68
14. Huchon GJ, Gialdroni-Grassi G, Leophonte P, et al. Initial antibacterial therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J 1996; 9: 1590-5
15. Raherison C, Peray P, Poirier R, et al. Management of lower respiratory tract infections by French general practitioners: the AIR II study. Analyse Infections Respiratoires. Eur Respir J 2002; 19: 314-9
16. Llor C, Cots JM, Boada A, et al. Variability of antibacterial prescribing for respiratory tract infections in two European countries. Enferm Infecc Microbiol Clin 2005; 23: 598-604
17. Bjerrum L, Boada A, Cots JM, et al. Respiratory tract infections in general practice: considerable differences in prescribing habits between general practitioners in Denmark and Spain. Eur J Clin Pharmacol 2004; 60: 23-8
18. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibacterial prescribing for acute respiratory tract infections in adult primary care. JAMA 2003; 289: 719-25
19. Martinez FJ, Anzueto A. Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Am J Med 2005; 118: S39-44
20. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibacterial treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-64
21. Wilson R, Jones P, Schaberg T, et al. MOSAIC Study Group. Antibacterial treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337-42
22. Miravitlles M, Molina J, Brosa M. Eficacia clínica de moxifloxacino en el tratamiento de las agudizaciones de la bronquitis crónica. Revisión sistemática y meta-análisis. Arch Bronconeumol. In press
23. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-45
24. Gonzales R, Steiner JF, Sande Ma. Antibacterial prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997; 278: 901-4
25. Metlay JP, Stafford RS, Singer DE. National trends in the use of antibacterials by primary care physicians for adult patients with cough. Arch Intern Med 1998; 158: 1813-8
26. Llor C, Naberan K, Cots JM, et al. Estudio EFEMAP. Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Arch Bronconeumol 2006; 42: 175-82
27. Miravitlles M, Llor C, Naberan K, et al. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med 2005; 99: 955-65
28. Niederman MS, Anzueto A, Sethi S, et al. Eradication of H. influenzae in AECB: a pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med 2006; 100: 1781-90